
Osimertinib improves overall survival in untreated EGFR-mutated advanced non-small cell lung cancer
Mature results of the FLAURA trial
0 COMENTÁRIOSMature results of the FLAURA trial
0 COMENTÁRIOSAdvances sustained by molecular classification in a universe of unknown possibilities
1 COMENTÁRIOSBenefits sustained only on surrogate endpoints
1 COMENTÁRIOSTherapeutic options and toxicity profile
0 COMENTÁRIOS